Quantcast

Latest Oncology Stories

2014-09-29 08:30:43

- Median overall survival is encouraging for this patient population - BOULDER, Colo., Sept. 29, 2014 /PRNewswire/ -- Final results from a Phase 2 trial of binimetinib in patients with advanced NRAS mutant melanoma were presented today at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid, Spain. Invented by Array BioPharma Inc. (NASDAQ: ARRY) and licensed to Novartis in 2010, binimetinib is a small molecule selective inhibitor of the kinases MEK1 and MEK2....

2014-09-29 08:29:30

Follows CytRx's Strategy to Develop a Global Oncology Franchise in Numerous Orphan Indications LOS ANGELES, Sept. 29, 2014 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted multiple Orphan Drug Designations for the Company's lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme (GBM), small cell lung...

roche
2014-09-29 05:16:14

Chuck Bednar for redOrbit.com - Your Universe Online Perjeta, a new breast cancer drug developed by Swiss pharmaceutical company Roche, has shown “unprecedented” success in extending the lives of patients in a clinical trial, according to research results released on Sunday. According to Andrew Pollack of the New York Times, patients who took the drug had a median survival period nearly 16 months longer than those in the control group – the longest time ever for a drug used as an...

2014-09-28 08:21:14

Final analysis of Phase 3 COU-AA-302 study presented at the European Society for Medical Oncology (ESMO) 2014 Congress HORSHAM, Pa., Sept. 28, 2014 /PRNewswire/ -- A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA(®) (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men...

2014-09-27 23:01:33

The Firm is evaluating potential legal claims on behalf of women who allegedly experienced the spread of uterine cancers due to the use of power morcellators in gynecological surgeries. New York, New York (PRWEB) September 27, 2014 The controversy involving power morcellators (http://www.gynecaremorcellatorlawsuit.com/) and their potential to spread uterine cancer was featured on a segment that aired on the popular Dr. Oz Show on September 24, 2014, Bernstein Liebhard LLP reports. During...

2014-09-27 08:21:20

- Global winners selected for their unique research projects that have the potential to advance research for the personalized treatment of solid tumors ROCKLAND, Mass., Sept. 27, 2014 /PRNewswire/ -- EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, today announced the winners of the first Grant for Oncology Innovation (GOI), who will receive grants totaling $1.3 million. The 2014 winners were formally announced at an awards ceremony coinciding with the annual...

2014-09-27 08:21:15

- AbbVie presents preliminary data from randomized phase 2 trial of veliparib in non-small cell lung cancer NORTH CHICAGO, Ill., Sept. 27, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with...

2014-09-26 23:07:28

The Arkansas Mesothelioma Victims Center is extremely focused on making certain all diagnosed victims in Arkansas, or their family members have instant access to two, or three of the nation's best mesothelioma compensation lawyers, to ensure the victim really does get the best possible compensation. For more information about this new campaign diagnosed victims of mesothelioma, or their family members are urged to contact the Arkansas Mesothelioma Victims Center anytime at...

2014-09-26 23:00:31

Radiopaque Solutions, Inc. has developed flexible x-ray visible micro marker bands for minimally invasive catheter applications. Device engineers have a new tool to help surgoens visualize devices during procedures. Bonita Springs, FL (PRWEB) September 27, 2014 Radiopaque Solutions, Inc., the world leader in x-ray visible materials technology, has developed a new micro marker band for extremely small devices. The bands, complement the current product offering of mid range and large...

2014-09-26 08:25:57

WASHINGTON, Sept. 26, 2014 /PRNewswire/ -- The Mesothelioma Compensation Center is challenging diagnosed victims or their family members to call them at 866-714-6466 before hiring an attorney to advance a mesothelioma compensation claim, because as the Center would like to explain, the lawyers they suggest typically get the best compensation results for their clients nationwide. http://MesotheliomaCompensationCenter.Com Photo - http://photos.prnewswire.com/prnh/20140925/148396 Photo...


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin